Morgan Stanley, Eagle Materials, Axon Enterprise And More: CNBC’s ‘Final Trades’

On CNBC's “Halftime Report Final Trades,” Rob Sechan of NewEdge Wealth named Eagle Materials Inc.

On CNBC’s “Halftime Report Final Trades,” Rob Sechan of NewEdge Wealth named Eagle Materials Inc. (NYSE:EXP) as his final trade.

On May 17, Eagle Materials announced plans to modernize and expand its cement plant in Laramie, Wyoming.

Sarat Sethi of DCLA said Morgan Stanley (NYSE:MS) hit the $100 level on the way up.

Morgan Stanley, last week, declared a substantial $269.9 million investment in spot Bitcoin (CRYPTO: BTC) ETFs through Grayscale’s (OTC:GBTC) in their first quarter 13F filing.

Don’t forget to check out our premarket coverage here

Shannon Saccocia of NB Private Wealth picked iShares U.S. Real Estate ETF (NYSE:IYR) as her final trade.

Joseph M. Terranova of Virtus Investment Partners named Axon Enterprise, Inc. (NASDAQ:AXON).

On May 6, Axon Enterprise posted better-than-expected results for its first quarter, reporting adjusted earnings of $1.15 per share beating market estimates of 94 cents per share. The company’s quarterly sales came in at $460.736 million versus expectations of $441.566 million. Axon raised its FY24 revenue outlook and also announced plans to acquire Dedrone, a global leader in airspace security.

Price Action:

  • Eagle Materials shares rose 0.3% to close at $256.97 on Monday.
  • Morgan Stanley gained 0.1% to settle at $100.33 during Monday’s session.
  • iShares U.S. Real Estate ETF fell 0.7% during Monday’s session.
  • Axon Enterprise shares rose 1.1% to close at $292.03 on Monday.

Check This Out: $3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Image: Shutterstock

Total
0
Shares
Related Posts
Read More

What’s Going On With Pfizer On Thursday? Pharma Giant’s Shares Tick Lower

Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys aged 4 to 7 using a modified human dystrophin gene, the trial showed no significant progress, affecting Pfizer's quest for new treatments as it diversifies beyond its COVID-19 portfolio.

PFE